

**REMARKS**

Claims 1-4, 7, 8, 10-13 and 25 were pending in the application. Claims 1-4, 7-8 and 10 have been amended. New claims 26 and 27 have been added. Accordingly, claims 1-4, 7, 8, 10-13 and 25-27 are currently pending.

Support for the amendments to claims 1-4, 7-8 and 10 and new claims 26 and 27 can be found throughout the specification and the claims as originally filed, for example, at least at the pages set forth below.

<b>Claim</b>	<b>Support in Specification</b>
Claims 1-4, 7-8 and 10	Page 2, lines 7-25; page 9, line 19 through page 10, line 8; page 10, lines 16-26; page 13, lines 9-20
Claim 26	Page 2, lines 7-20; page 10, lines 16-26
Claim 27	Page 2, lines 7-20; page 10, lines 16-26; Example 3

*No new matter has been added.* Any amendment and/or cancellation of the claims should in no way be construed as an acquiescence to any of the Examiner's rejections and was performed solely to expedite prosecution of the application. Applicants reserve the right to pursue the claims as originally filed in this or a separate application(s).

***Acknowledgment of the Examiner's Withdrawal of Rejection***

Applicants gratefully acknowledge the Examiner's withdrawal of the following: (a) The objection to the specification and (b) The rejection of claims 1-3, 7-8, 10-13 and 25 under 35 U.S.C. § 112, paragraph 2.

***Rejection of Claims 1-4, 7, 8, 10-13 and 25 Under 35 U.S.C. § 112, First Paragraph***

The Examiner maintains the rejection of claims 1-4, 7-8, 10-13 and 25 under 35 U.S.C. § 112, first paragraph, as failing to comply with the written description requirement. Specifically, the Examiner states that the:

claimed genus of polynucleotides encompasses potentially a large number of DNA fragments of various sizes and from different animal species...The specification does not describe a regulatory element of any size in any other non-human animal that can direct testis or ovary specific gene transcription. The specification also fails describe any fragments larger than 261 bp isolated from either 5' or 3' of the mouse GDF-9 gene or in any intron of the GDF-9 gene that can direct ovary or testis specific transcription...The instant specification only discloses one nucleic acid sequence capable of promoting expression in ovary and testis, the mouse 3.3 kb fragment immediately 5' to the GDF-9 gene, one fragment that directs expression in ovary, but not testis, the mouse 10kb fragment immediately 5' to the GDF-9 gene. In view of the large genus that is claimed, this hardly represents a number of species.

The Examiner further states that:

the specification fails to teach what is the critical/essential element that the claimed polynucleotide must have for its function of regulating expression in oocyte or testis...The disclosure of methods for identifying the claimed invention is not itself a description of the structure of the claimed invention. The disclosure of the method of testing whether the claimed invention has regulatory function in oocyte or testis does not constitute the description of the structure of the claimed invention either. As such, the specification fails to describe the claimed invention in such a way to convey one skilled in the art that Applicants had possession of the invention at the time the application is filed.

While in no way acquiescing to the Examiner's rejection, and solely in the interest of expediting prosecution, Applicants have amended claims 1-4, 7-8 and 10. The claims, as amended, are drawn to isolated polynucleotides having specific structural and functional characteristics. Specifically, the claimed polynucleotides are capable of regulating expression of an operably linked gene in oocytes or testis. Further, the claimed polynucleotides include the first 10 kilobases of DNA of the murine GDF-9 gene immediately 5' of the transcription start site or DNA at least 95% identical thereto, the first 3.3 kilobases of DNA of the murine GDF-9 gene immediately 5' of the transcription start site or DNA at least 95% identical thereto, the first 1 kilobase of DNA of the murine GDF-9 gene immediately 3' of the transcription termination site. The claims are also drawn to portions of the foregoing polynucleotides wherein the portion

is at least 300 nucleotides in length. Based on Applicants' teachings (described below) and the level of skill in the art, one of ordinary skill would have recognized that Applicants were in possession of the claimed invention.

An objective standard for determining compliance with the written description requirement under 35 U.S.C. § 112, first paragraph, is whether the specification conveys with reasonable clarity to those skilled in the art that, as of the filing date sought, the applicants were in possession of the invention as now claimed. *Vas-Cath, Inc. v. Mahurkar*, 935 F.2d 1555, 1563-64, 19 USPQ2d 1111, 1117 (Fed. Cir. 1991) and *In re Gosteli*, 872 F.2d 1008, 1012, 10 USPQ2d 1614, 1618 (Fed. Cir. 1989). Furthermore, pursuant to MPEP § 2163(II)(D) "[f]actors to be considered in determining whether there is sufficient evidence of possession include the level of skill and knowledge in the art, partial structure, physical and/or chemical properties, functional characteristics alone or coupled with a known or disclosed correlation between structure and function, and the method of making the claimed invention. Disclosure of any combination of such identifying characteristics that distinguish the claimed invention from other materials and would lead one of skill in the art to the conclusion that the applicant was in possession of the claimed species is sufficient. See *Eli Lilly*, 119 F.3d at 1568, 43 USPQ2d at 1406."

Indeed, it is firmly established that the descriptive text needed to meet the Written Description requirement varies with the nature and scope of the invention at issue, and with the scientific and technologic knowledge already in existence. *Capon v. Eshhar*, 418 F.3d 1349, 1357 (Fed. Cir. 2005). In *Capon*, the Federal Circuit explained that "since the law is applied to each invention in view of the state of the relevant knowledge, its application will vary with differences in the state of knowledge in the field and differences in the predictability of the science." *Id.* Specifically, the Court stated that:

Precedent illustrates that the determination of what is needed to support generic claims to biological subject matter ***depends on a variety of factors, such as the existing knowledge in the particular field, the extent and content of the prior art, the maturity of the science or technology, the predictability of the aspect at issue, and other considerations appropriate to the subject matter.*** *Id.* at 1359 (emphasis added).

For example, Applicants' disclosure provides methods for identifying the claimed GDF-9 regulatory elements, including those with a nucleotide sequence at least 95% identical to murine

GDF-9<sup>1</sup> (see, *e.g.*, page 11, line 26 through page 13, line 20) of the instant specification.

Moreover, Applicants disclose assays to test whether these variants are capable of regulating expression of an operably linked gene in oocytes or testis (see page 16, lines 5-18 of the instant specification). Applicants' disclosure also provides a detailed description of how to identify and characterize the claimed GDF-9 molecules from variety of sources including mammalian and avian genomic cDNA libraries or synthesized from a variety of known and sequenced GDF-9 genes (see, *e.g.*, page 9, line 19 through page 13, line 29). Applicants further teach methods for preparing expression vectors which comprise the identified regulatory elements, as well as methods for transfecting cells with such vectors (see, *e.g.*, page 14, line 1 through page 16, line 29). Further, the specification provides working examples which demonstrate how to the claimed molecules can be tested for regulating expression of genes as claimed (see, *e.g.*, page 19, line 6 through page 22, line 4). Moreover, as indicated by the Guidelines, "procedures for making variants...which have 95% identity...and retain its activity are conventional in the art."

With regard to the claimed polynucleotide portions which are at least 300 nucleotides in length, Applicants teach in the present specification that the sizes of the regulatory elements are variable (see, *e.g.*, page 7, lines 4-5). Applicants further identify (at page 11, lines 3-25) the presence of a testis-specific repressor element in the region from 3.3 to 10 kilobases immediately 5' of the transcription initiation site of the mouse GDF-9 gene. Accordingly, based on the level of skill in the art at the time the present application was filed, Applicants teach that "[f]urther mapping of such promoter and repressor elements can be achieved by similarly testing smaller fragments of these regions to define the particular sequences involved in gene regulation." Applicants also teach that other functional mapping techniques also may be employed to further characterize and identify specific GDF-9 regulatory sequences.

For example, nucleotide bases within these regions (*e.g.*, the 0.3, 3.3 or 10 kilobase fragments of the 5' region) can be mutated by, for example site-directed mutagenesis, to add, delete or change one or more bases (*e.g.*, 6-12 bases), followed by testing the mutated regulatory sequences for activity either *in vitro* (*e.g.*, by microinjection or transfection) or *in vivo* (*e.g.*, in a transgenic animal) to see what functional effect the mutation had. From this information, nucleotide bases required for function (*e.g.*, upregulation or downregulation) of the regulatory element can be determined. For example, if upon mutating a small (*e.g.*, 6-12 base pair) segment of the 5' region of a GDF-9 gene, transcription levels of a reporter gene operatively linked to the 5' region are diminished, then

---

<sup>1</sup> Applicants draw the Examiner's attention to Example 14 of the Revised Interim Written Description Guidelines, Training Material (published in the Federal Register on December 21, 1999).

this small region can be concluded to be involved in promoting transcription (e.g., by binding to one or more transcription factors). Transcription factors that bind cis-acting regulatory elements may also interact with each other. Therefore, multiple reporter constructs can be developed and tested for the interaction between their potential cis-elements and such binding proteins using the assays described herein.

Alternatively, according to Applicants, “regulatory regions of GDF-9 genes can be identified by comparing untranscribed upstream and downstream regions, and transcribed, untranslated regions of a GDF-9 gene with 5’ and 3’ sequences from other known genes, for example, which are expressed in a similar tissue-specific pattern and, therefore, which may contain related or homologous regulatory elements.” (see, *e.g.*, page 12, lines 14-27). Applicants further exemplify a polynucleotide which is 300 nucleotide in length and which contains a conserved domain that has been shown to bind basic helix-loop-helix transcription factors, many of which are tissue-specific (Liang et al. (1997) *Development* 124:4939-4947).


Thus, based on the extensive teachings in Applicants’ specification regarding the structural and functional properties of the claimed regulatory elements, as well as the knowledge generally available in the art, the skilled artisan would understand that Applicants were in possession of the claimed invention at the time of filing. Accordingly, the requirement of 35 U.S.C. § 112, First Paragraph for written description has been satisfied and Applicants respectfully request reconsideration and withdrawal of this rejection.

**CONCLUSION**

In view of the above amendments and remarks set forth above, it is respectfully submitted that this application is in condition for allowance. If there are any remaining issues or the Examiner believes that a telephone conversation with Applicants' Attorney could be helpful in expediting prosecution of this application, the Examiner is invited to call the undersigned at (617) 227-7400.

Dated: December 28, 2005

Respectfully submitted,

By   
\_\_\_\_\_  
Jacob G. Weintraub  
Registration No.: 56,469  
For Jeanne M. DiGiorgio  
Registration No.: 41,710  
LAHIVE & COCKFIELD, LLP  
28 State Street  
Boston, Massachusetts 02109  
(617) 227-7400  
(617) 742-4214 (Fax)  
Attorney/Agent For Applicants